Your browser doesn't support javascript.
loading
A Cell Biologist's Field Guide to Aurora Kinase Inhibitors.
de Groot, Christian O; Hsia, Judy E; Anzola, John V; Motamedi, Amir; Yoon, Michelle; Wong, Yao Liang; Jenkins, David; Lee, Hyun J; Martinez, Mallory B; Davis, Robert L; Gahman, Timothy C; Desai, Arshad; Shiau, Andrew K.
Afiliação
  • de Groot CO; Small Molecule Discovery Program, Ludwig Institute for Cancer Research , La Jolla, CA , USA.
  • Hsia JE; Small Molecule Discovery Program, Ludwig Institute for Cancer Research , La Jolla, CA , USA.
  • Anzola JV; Small Molecule Discovery Program, Ludwig Institute for Cancer Research , La Jolla, CA , USA.
  • Motamedi A; Small Molecule Discovery Program, Ludwig Institute for Cancer Research , La Jolla, CA , USA.
  • Yoon M; Small Molecule Discovery Program, Ludwig Institute for Cancer Research , La Jolla, CA , USA.
  • Wong YL; Laboratory of Chromosome Biology, Ludwig Institute for Cancer Research, La Jolla, CA, USA; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
  • Jenkins D; Small Molecule Discovery Program, Ludwig Institute for Cancer Research , La Jolla, CA , USA.
  • Lee HJ; Small Molecule Discovery Program, Ludwig Institute for Cancer Research , La Jolla, CA , USA.
  • Martinez MB; Small Molecule Discovery Program, Ludwig Institute for Cancer Research , La Jolla, CA , USA.
  • Davis RL; Small Molecule Discovery Program, Ludwig Institute for Cancer Research , La Jolla, CA , USA.
  • Gahman TC; Small Molecule Discovery Program, Ludwig Institute for Cancer Research , La Jolla, CA , USA.
  • Desai A; Laboratory of Chromosome Biology, Ludwig Institute for Cancer Research, La Jolla, CA, USA; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
  • Shiau AK; Small Molecule Discovery Program, Ludwig Institute for Cancer Research , La Jolla, CA , USA.
Front Oncol ; 5: 285, 2015.
Article em En | MEDLINE | ID: mdl-26732741
ABSTRACT
Aurora kinases are essential for cell division and are frequently misregulated in human cancers. Based on their potential as cancer therapeutics, a plethora of small molecule Aurora kinase inhibitors have been developed, with a subset having been adopted as tools in cell biology. Here, we fill a gap in the characterization of Aurora kinase inhibitors by using biochemical and cell-based assays to systematically profile a panel of 10 commercially available compounds with reported selectivity for Aurora A (MLN8054, MLN8237, MK-5108, MK-8745, Genentech Aurora Inhibitor 1), Aurora B (Hesperadin, ZM447439, AZD1152-HQPA, GSK1070916), or Aurora A/B (VX-680). We quantify the in vitro effect of each inhibitor on the activity of Aurora A alone, as well as Aurora A and Aurora B bound to fragments of their activators, TPX2 and INCENP, respectively. We also report kinome profiling results for a subset of these compounds to highlight potential off-target effects. In a cellular context, we demonstrate that immunofluorescence-based detection of LATS2 and histone H3 phospho-epitopes provides a facile and reliable means to assess potency and specificity of Aurora A versus Aurora B inhibition, and that G2 duration measured in a live imaging assay is a specific readout of Aurora A activity. Our analysis also highlights variation between HeLa, U2OS, and hTERT-RPE1 cells that impacts selective Aurora A inhibition. For Aurora B, all four tested compounds exhibit excellent selectivity and do not significantly inhibit Aurora A at effective doses. For Aurora A, MK-5108 and MK-8745 are significantly more selective than the commonly used inhibitors MLN8054 and MLN8237. A crystal structure of an Aurora A/MK-5108 complex that we determined suggests the chemical basis for this higher specificity. Taken together, our quantitative biochemical and cell-based analyses indicate that AZD1152-HQPA and MK-8745 are the best current tools for selectively inhibiting Aurora B and Aurora A, respectively. However, MK-8745 is not nearly as ideal as AZD1152-HQPA in that it requires high concentrations to achieve full inhibition in a cellular context, indicating a need for more potent Aurora A-selective inhibitors. We conclude with a set of "good practice" guidelines for the use of Aurora inhibitors in cell biology experiments.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2015 Tipo de documento: Article